is a normal gut inhabitantthat can cause various diseases ,such as intestinal, urinary tract, bladder infections and systemic infections in humans and animals. The alarming increase in profiles for extended-spectrum β-lactamase- and carbapenemase-producing isolates is a serious problem throughout the world. Colistin is known as a lastresort agent for the treatment of Gram-negative bacterial infections. Inappropriate use of colistin and other classes of antibiotics combined with inadequate infection control, especially in developing countries, can lead to serious public health complications. The global increase in colistin resistance has been reported in many parts of the world, ,including the Middle East. Colistin is used to treat infections caused by extensively drug-resistant Gram-negative bacteria. There are few reliable epidemiologic data on colistin-resistant isolates, and information on colistin-resistant from Asia, the largest, most populous, and most diverse continent in the world, is generally limited compared with Europe and the United States. The data in this review article were compiled from related articles associated with isolated colistin-resistant () isolates from humans, animals, and food-producing animals. In the Middle East, colistin-resistant isolates were reported from Turkey, Egypt, Saudi Arabia, Algeria, Iran, Iraq, Bahrain, Qatar, Oman, Kuwait, Israel, and Lebanon between 2010 and 2023. While colistin resistance is most commonly observed in isolates, data have shown that mcr genes are the most common genes associated with colistin resistance in isolatescompared to mutations in , , and genes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11345471 | PMC |
http://dx.doi.org/10.32592/ARI.2024.79.1.13 | DOI Listing |
Microbiol Spectr
December 2024
Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Carbapenem-resistant complex (CR-ECC), which is rapidly increasing as the cause of nosocomial infections, has limited treatment options. The aim of this study is to investigate the microbiological and clinical traits and molecular epidemiology of isolates of CR-ECC and provide guidance for antibiotic selection in clinical practice. Clinical CR-ECC isolates (ertapenem MIC ≥ 2 mg/L) were collected from 2021 to 2022.
View Article and Find Full Text PDFBMC Res Notes
December 2024
Nosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Objective: The increase of multidrug-resistant (MDR) strains of Acinetobacter baumannii (A. baumannii), especially carbapenem-resistant strains, is challenging for treating infections. This study investigated the antibiotic resistance pattern and frequency of carbapenem resistance genes (oxacillinase and metallo-beta-lactamase) in A.
View Article and Find Full Text PDFPol J Vet Sci
December 2024
Department of Animal Nutrition and Husbandry, University of Veterinary Medicine and Pharmacy in Košice, Komenského 73, Košice, 04181, Slovakia.
The present study aimed to search for the presence of the plasmid-mediated antimicrobial resistance genes in 106 Escherichia coli (E. coli) isolates from a total of 240 fresh fecal samples collected from 12 private cattle farms in Bingol province of East Turkey from November 2021 to January 2022. In those colistin-resistant E.
View Article and Find Full Text PDFJ Chemother
December 2024
Department of Pharmacy, Yunus Emre Vocational School, Anadolu University, Eskişehir, Turkey.
Novel therapeutic interventions are required to address the critical antimicrobial resistance caused by multidrug-resistant (MDR-PA) infections. This study examines the impact of combining delafloxacin with antibiotics on MDR-PA isolated from various samples. The minimum inhibitory concentrations (MICs) of delafloxacin, alone and in combination with other antibiotics, were determined against forty distinct MDR-PA isolates using the broth microdilution method.
View Article and Find Full Text PDFFront Cell Infect Microbiol
December 2024
Servicio de Microbiología, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
Introduction: Murepavadin is an antimicrobial peptide (AMP) in clinical development that selectively targets LptD and whose resistance profile remains unknown. We aimed to explore genomic modifications and consequences underlying murepavadin and/or colistin susceptibility.
Methods: To define genomic mechanisms underlying resistance, we performed two approaches: 1) a genome-wide association study (GWAS) in a clinical collection (n=496), considering >0.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!